七种抗精神病药治疗精神分裂症急性加重期的疗效与耐受性:一项随机、多中心、评估者盲法试验
该多中心、行业独立、平行、评估者盲法、灵活剂量随机试验纳入3,067例18-45岁精神分裂症急性加重住院患者,比较七种抗精神病药单药治疗6周的疗效与耐受性。奥氮平和利培酮第6周PANSS评分百分比变化显著高于阿立哌唑、齐拉西酮和喹硫平,但与氟哌啶醇或奋乃静无显著差异。各药在体重增加、高催乳素血症、代谢副作用、锥体外系症状、镇静及全因停药率方面呈现不同风险层级。
要点
- 奥氮平和利培酮第6周PANSS改善显著优于阿立哌唑、齐拉西酮和喹硫平。
- 奥氮平体重增加风险最高,氟哌啶醇锥体外系症状风险最高。
- 阿立哌唑高催乳素血症风险最低且镇静最轻,齐拉西酮和阿立哌唑体重增加及代谢副作用风险较低。
核心结论
- 该试验填补了精神分裂症急性期抗精神病药治疗的重要知识空白,并证实了相关证据中抗精神病药在疗效和副作用方面的层级关系。
研究设计与样本
- 多中心(32家医院)、行业独立、平行、评估者盲法、灵活剂量随机试验(Schizophrenia in Non-Occidental Participants)。
- 纳入18-45岁精神分裂症急性加重住院患者,随机接受奥氮平、利培酮、喹硫平、阿立哌唑、齐拉西酮、奋乃静或氟哌啶醇单药治疗6周。
- 共随机3,067例患者,82%完成随访。
主要发现
- 混合模型显示七种抗精神病药主要结局PANSS评分百分比变化存在显著差异。
- 第6周奥氮平和利培酮PANSS评分百分比变化显著高于阿立哌唑、齐拉西酮和喹硫平(平均差异:5.52-7.93),但与氟哌啶醇或奋乃静无显著差异。
- 奥氮平体重增加风险最高(相对风险:1.44-3.22)。
- 阿立哌唑高催乳素血症风险低于所有其他药物(相对风险:0.11-0.21)。
- 齐拉西酮和阿立哌唑体重增加及代谢副作用风险较低。
临床怎么用
- 临床选择抗精神病药时需权衡疗效与副作用风险层级,奥氮平和利培酮疗效较高但奥氮平体重增加风险最高。
- 氟哌啶醇锥体外系症状风险较高,阿立哌唑高催乳素血症风险最低且镇静最轻。
- 齐拉西酮和阿立哌唑体重增加及代谢副作用风险较低,但奥氮平和利培酮全因停药率低于齐拉西酮和氟哌啶醇。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antipsychotic drugs are the mainstay of schizophrenia treatment; yet, controversy persists regarding their relative efficacy and side effects, and guideline recommendations on efficacy differences are particularly vague. The aim of this trial was to compare seven antipsychotics in acutely ill patients with schizophrenia. METHODS: The authors performed a multicenter (32 hospitals), industry-independent, parallel, assessor-blinded, flexible-dosage randomized trial (Schizophrenia in Non-Occidental Participants). Eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation were recruited and randomized to 6 weeks of monotherapy with one of seven antipsychotic drugs: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, perphenazine, and haloperidol. RESULTS: A total of 3,067 patients were randomized, of whom 82% completed follow-up. The mixed model indicated significant differences in the primary outcome percentage change in Positive and Negative Syndrome Scale (PANSS) score between the antipsychotics. At week 6, olanzapine and risperidone showed a significantly higher percentage change in PANSS score than aripiprazole, ziprasidone, and quetiapine (mean differences: 5.52-7.93) but not haloperidol or perphenazine. Olanzapine was associated with the highest risk of weight gain (relative risk: 1.44-3.22). Aripiprazole was associated with lower risk of hyperprolactinemia than all the other drugs (relative risks: 0.11-0.21). Ziprasidone and aripiprazole were associated with lower risks of weight gain and metabolic side effects. Haloperidol was associated with a higher risk of extrapyramidal symptoms than all other drugs (relative risks: 0.13-0.61). Aripiprazole was least sedating (relative risks: 0.30-0.39). Olanzapine and risperidone showed lower all-cause discontinuation rates than ziprasidone and haloperidol (hazard ratios: 0.61-0.73). CONCLUSIONS: This trial fills important knowledge gaps in acute antipsychotic treatment of schizophrenia. It confirms hierarchies in efficacy and side effects of antipsychotics from related evidence.
引用
- Zhao G, Sun Y, Zhang Y, et al. Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial. Am J Psychiatry. 2025. PMID: 41152254. doi:10.1176/appi.ajp.20250111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。